Novavax | NVAX - Operating Expenses


Novavax reported $126.2M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Adma Biologics USD 71.95M 7.75M Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
AstraZeneca USD 11.55B 674M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Cassava Sciences USD 9.39M 1.78M Jun/2026
Geron USD 54.46M 15.67M Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
MannKind USD 104.44M 5.77M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.18B 223M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Sanofi EUR 10.51B 598M Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026